Advertisement

Silence Therapeutics plc SLN

Set alert

Price alert · SLN

All alert types
19.75 USD -0.05 -0.25%

At close · Oct 30

19.75 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
19.75 × 2
Ask
19.76 × 2
19.74 Day range 19.80
4.30 52-week range 19.80
YTD
+224.84%
1 year
+170.18%
Open
19.74
Prev close
19.80
Mkt cap
1.23B
Vol
621.43K
Avg vol
2.77M
EPS
-1.29
P/E
0.00
Div yield
0.00%
More statistics
Low
19.74
High
19.80
Forward P/E
-51.97
Beta
1.45
Short ratio
2.70
Inst. own
47.74%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
13.35
200-d avg
8.99
1y target
19.75

5D chart

Chart tools
Interval

Signals (39)
NameTimeAgo
RSI: OverboughtOct 29, 3:40 PM2 days ago
RSI: OverboughtOct 29, 3:25 PM2 days ago
MACD: Buy SignalOct 29, 2:45 PM2 days ago
SMA: BullishOct 29, 12:45 PM2 days ago
MACD: Sell SignalOct 29, 12:25 PM2 days ago
MACD: Buy SignalOct 29, 11:05 AM2 days ago
MACD: Sell SignalOct 29, 10:50 AM2 days ago
MACD: Buy SignalOct 29, 9:35 AM2 days ago
SMA: BullishOct 29, 9:30 AM2 days ago
RSI: OversoldOct 28, 3:55 PM3 days ago
MACD: Sell SignalOct 28, 3:50 PM3 days ago
MACD: Buy SignalOct 28, 2:50 PM3 days ago
MACD: Sell SignalOct 28, 1:35 PM3 days ago
MACD: Buy SignalOct 28, 1:25 PM3 days ago
MACD: Sell SignalOct 28, 12:45 PM3 days ago
RSI: OversoldOct 28, 12:45 PM3 days ago
MACD: Buy SignalOct 28, 10:40 AM3 days ago
SMA: BearishOct 28, 9:30 AM3 days ago
SMA: BearishOct 28, 9:30 AM3 days ago
MACD: Sell SignalOct 28, 9:30 AM3 days ago
SMA: BullishOct 27, 3:30 PM4 days ago
SMA: BullishOct 27, 3:30 PM4 days ago
MACD: Buy SignalOct 27, 3:30 PM4 days ago
MACD: Sell SignalOct 27, 3:25 PM4 days ago
SMA: BullishOct 27, 2:45 PM4 days ago
MACD: Buy SignalOct 27, 2:40 PM4 days ago
MACD: Sell SignalOct 27, 12:30 PM4 days ago
RSI: OverboughtOct 27, 11:35 AM4 days ago
MACD: Buy SignalOct 27, 11:15 AM4 days ago
SMA: BearishOct 27, 9:45 AM4 days ago
SMA: BearishOct 27, 9:45 AM4 days ago
SMA: BullishOct 27, 9:40 AM4 days ago
SMA: BearishOct 27, 9:35 AM4 days ago
SMA: BearishOct 26, 3:40 PM5 days ago
MACD: Sell SignalOct 26, 3:10 PM5 days ago
RSI: OverboughtOct 26, 1:55 PM5 days ago
MACD: Buy SignalOct 26, 1:10 PM5 days ago
SMA: BearishOct 26, 12:00 PM5 days ago
RSI: OverboughtOct 26, 11:15 AM5 days ago

Key statistics

Market cap
1.23B
Enterprise value
863.54M
Trailing P/E
0.00
Forward P/E
-51.97
PEG ratio
0.00
Price / sales
1997.58
Price / book
24.26
EPS (TTM)
-1.29
Beta
1.45
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
615.00K
Revenue growth
0.00%
Free cash flow
-23.57M
Total cash
72.05M
Total debt
112.00K
Return on equity
-90.41%
Shares outstanding
62.20M
Short % of float
5.78%
50-day average
13.35
200-day average
8.99

Analyst view

Consensus: hold

Hold
Price target (mean) 19.75 0.0% upside
Target (low)
19.00
Target (mean)
19.75
Target (high)
20.00
Ratings (0m) 5 1 buy · 4 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold4
  • Sell0
  • Strong sell0

Next earnings

Nov 5, 2026

Expected Nov 5, 2026. Consensus EPS estimate -0.09.

Earnings history

Financials — quick view

All financials
SLN Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
SLN Net income — quarterly -12.27M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
SLN EPS — quarterly -0.27
2024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

SLN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 2026-0.11289———
Aug 10, 2026Jun 30, 2026-0.13866-0.26-0.12-87.51%
May 7, 2026Mar 31, 2026-0.33-0.32+0.01+3.03%
Mar 5, 2026Dec 31, 2025-0.32-0.25+0.07+21.88%
Nov 6, 2025Sep 30, 2025-0.40-0.45-0.05-12.50%
Aug 7, 2025Jun 30, 2025-0.27-0.54-0.27-100.00%

Upgrades / downgrades

SLN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 21, 2026HC Wainwright & Co.downBuyNeutral
Aug 11, 2026Morgan StanleymainOverweightOverweight
Jun 24, 2026Cantor Fitzgeraldinit—Overweight
Jun 17, 2026HC Wainwright & Co.reitBuyBuy
Mar 13, 2026HC Wainwright & Co.reitBuyBuy
Sep 16, 2025HC Wainwright & Co.reitBuyBuy

About Silence Therapeutics plc

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Country
United Kingdom

News

Your note

Sign in to keep a note on SLN — it syncs with the Stock Master app.

Institution ownership

SLN institution ownership
Holder% heldSharesValueReported
Siren, L.L.C.5.50%3,311,43865.40MJun 29, 2026
TCG Crossover Management, LLC5.04%3,033,56059.91MJun 29, 2026
Redmile Group, LLC3.60%2,164,77742.75MJun 29, 2026
Nantahala Capital Management, LLC2.24%1,346,73126.60MJun 29, 2026
Citadel Advisors Llc2.21%1,329,62526.26MJun 29, 2026
Nextech Invest, Ltd.1.58%952,40018.81MJun 29, 2026

Fund ownership

SLN fund ownership
Holder% heldSharesValueReported
Fidelity Select Portfolios-Select Biotechnology Portfolio3.39%2,042,90040.35MAug 30, 2026
Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund0.88%531,78810.50MAug 30, 2026
Fidelity Select Portfolios-Select Health Care Portfolio0.83%500,0009.88MAug 30, 2026
iShares Trust-iShares Biotechnology ETF0.48%289,9725.73MSep 29, 2026
Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund0.38%228,0004.50MAug 30, 2026
ALGER FUNDS-Alger Small Cap Growth Fund0.18%105,6792.09MJul 30, 2026
Advertisement